RxDoctor Payments Data

Ghulam Abbas, MD

Internal Medicine · Frederick, MDNPI 1477658045

Payments from drug & device makers

$1,718in general payments, 2019–2025

Across 23 payments — averaging $74.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Noah Medical Corporation$1K
  • Intuitive Surgical$182
  • Inspire Medical Systems, Inc.$106
  • Gilead$81
  • United Therapeutics Corporation$71
  • AbbVie$69
  • plus $120 from 5 others

What the payments were for

  • Travel & lodging$1,25573%
  • Food & beverage$46327%

General payments by program year

20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,718 in reported general payments places this provider in the 75th percentile of 2,979 internal medicine providers in Maryland.

See all internal medicine providers in Maryland

Medicare billing

Part B allowed, 2024
$432,153
Medicare patients
482
Services billed
3,965

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban627$227,410
JardianceEmpagliflozin445$185,961
ZenpepLipase/Protease/Amylase68$73,317
NuplazidPimavanserin Tartrate13$58,978
MyrbetriqMirabegron133$56,642
OzempicSemaglutide47$47,223
JanuviaSitagliptin Phosphate121$46,881
GemtesaVibegron86$39,252
XareltoRivaroxaban65$25,888
Atorvastatin Calcium1,324$19,799
EntrestoSacubitril/Valsartan29$19,204
Janumet XrSitagliptin Phos/Metformin Hcl42$18,619
LinzessLinaclotide31$17,786
MounjaroTirzepatide15$16,917
Tresiba Flextouch U-100Insulin Degludec128$14,281

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$26$227,410627 claims
Astellas Pharma US IncMyrbetriq$27$56,642133 claims
AbbVieLinzess, Restasis$69$24,85152 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 2,979 internal medicine providers in Maryland.

Other internal medicine in Frederick

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →